Product Data Sheet

CDK2-IN-12

Cat. No.: HY-150573

CAS No.: 2410402-88-7 $\text{Molecular Formula:} \qquad \text{C}_{20}\text{H}_{17}\text{N}_9\text{O}_2\text{S}$

Molecular Weight: 447.47

Target: CDK; Carbonic Anhydrase

Pathway: Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC $_{50}$ of 11.6 μ M. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with K $_{\rm I}$ values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity $^{[1]}$.	
IC ₅₀ & Target	CDK2 11.6 μM (IC ₅₀)	CDK9 >12.5 μM (IC ₅₀)
In Vitro	CDK2-IN-12 (compound 10b) exerts outstanding anti-proliferative activity against leukemia (CCRF-CEM, HL-60TB, K-562 and MOLT-4), non-small cell lung cancer (HOP-92), colon cancer (COLO 205, HCT-116 and SW-620), renal (ACHN) and breast (MDA-MB-468) cell lines with GI% (percentage growth inhibition) ranging from 80 to $100\%^{[1]}$. CDK2-IN-12 displays much enhanced growth inhibitory activity, under normoxic and hypoxic conditions, against MDA-MB-468 (IC50 = 1.37 ± 0.07 and $3.03\pm0.11~\mu$ M) than MCF-7 cells (IC50 = 6.80 ± 0.17 and $15.10\pm0.82~\mu$ M) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Said MA, et al. Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation. Eur J Med Chem. 2020 Mar 1;189:112019.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

E-mail: tech@MedChemExpress.com

Tel: 609-228-6898 Fax: 609-228-5909

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA